Company Overview of Romark Laboratories, L.C.
Romark Laboratories, L.C., a pharmaceutical company, discovers, develops, and commercializes small molecules for treating infectious diseases and cancers. It provides thiazolide and nitazoxanide antiviral drugs for treatment of chronic hepatitis C and influenza. The company was founded in 1993 and is headquartered in Tampa, Florida.
3000 Bayport Drive
Tampa, FL 33607
Founded in 1993
Key Executives for Romark Laboratories, L.C.
Chief Operating Officer and Executive Vice President
Compensation as of Fiscal Year 2014.
Romark Laboratories, L.C. Key Developments
Romark Laboratories L.C. to Open Plant in Puerto Rico
Dec 5 14
Romark Laboratories L.C. is building a $110 million plant in the U.S. territory. Construction will begin in January and that nearly 200 jobs will be created in three years. The plant is expected to manufacture and package Heartgard and Heartgard Plus products. The plant is expected to manufacture and package Heartgard and Heartgard Plus products.
Romark Laboratories, L.C. Wins $2 Million Federal Contract
Jun 5 14
Romark Laboratories, L.C. won a $2 million federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Hines, Illinois, for medical equipment and supplies.
Romark Laboratories, L.C. and Lupin Limited Reach Strategic Agreement for Promotion and Distribution Of Alinia for Oral Suspension
Aug 7 13
Romark Laboratories, L.C. announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia(R) (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States. Lupin will promote the product using the pediatric-focused sales force of Lupin Pharmaceuticals. Alinia for Oral Suspension is approved by the U.S. Food and Drug Administration for treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 months of age and older. The product has not been shown to be superior to placebo for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients. It is the only product approved for treatment of diarrhea caused by Cryptosporidium parvum and the only product approved in the United States for treating diarrhea caused by Giardia lamblia in children under 4 years of age. Cryptosporidium and Giardia are the two most common protozoan infections in the United States and worldwide. The U.S. Centers for Disease Control and Prevention (CDC) estimates that there are approximately 1.2 million cases of Giardia infection and 750,000 cases of Cryptosporidium infection annually in the United States, although most of these infections are undiagnosed. Romark will continue to promote and distribute Alinia (nitazoxanide) tablets, 500 mg, with its specialty sales force focused primarily on gastroenterologists and primary care physicians. The Company has recently expanded its specialty sales force from 16 to 30 representatives and plans to further expand to 50 representatives before the end of 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 27, 2014
Most Searched Private Companies
Sponsored Financial Commentaries